SOLID BIOSCIENCES INC (SLDB) Fundamental Analysis & Valuation

NASDAQ:SLDB • US83422E2046

Current stock price

7.11 USD
-0.62 (-8.02%)
At close:
7.25 USD
+0.14 (+1.97%)
After Hours:

This SLDB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SLDB Profitability Analysis

1.1 Basic Checks

  • In the past year SLDB has reported negative net income.
  • SLDB had a negative operating cash flow in the past year.
  • In the past 5 years SLDB always reported negative net income.
  • In the past 5 years SLDB always reported negative operating cash flow.
SLDB Yearly Net Income VS EBIT VS OCF VS FCFSLDB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • With a Return On Assets value of -74.97%, SLDB perfoms like the industry average, outperforming 40.27% of the companies in the same industry.
  • With a Return On Equity value of -96.84%, SLDB perfoms like the industry average, outperforming 51.45% of the companies in the same industry.
Industry RankSector Rank
ROA -74.97%
ROE -96.84%
ROIC N/A
ROA(3y)-52.5%
ROA(5y)-48.03%
ROE(3y)-69.2%
ROE(5y)-61.82%
ROIC(3y)N/A
ROIC(5y)N/A
SLDB Yearly ROA, ROE, ROICSLDB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SLDB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLDB Yearly Profit, Operating, Gross MarginsSLDB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. SLDB Health Analysis

2.1 Basic Checks

  • SLDB has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, SLDB has more shares outstanding
  • There is no outstanding debt for SLDB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SLDB Yearly Shares OutstandingSLDB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
SLDB Yearly Total Debt VS Total AssetsSLDB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • SLDB has an Altman-Z score of -1.09. This is a bad value and indicates that SLDB is not financially healthy and even has some risk of bankruptcy.
  • With a decent Altman-Z score value of -1.09, SLDB is doing good in the industry, outperforming 61.66% of the companies in the same industry.
  • There is no outstanding debt for SLDB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.09
ROIC/WACCN/A
WACCN/A
SLDB Yearly LT Debt VS Equity VS FCFSLDB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • SLDB has a Current Ratio of 6.14. This indicates that SLDB is financially healthy and has no problem in meeting its short term obligations.
  • SLDB's Current ratio of 6.14 is fine compared to the rest of the industry. SLDB outperforms 66.67% of its industry peers.
  • A Quick Ratio of 6.14 indicates that SLDB has no problem at all paying its short term obligations.
  • SLDB has a Quick ratio of 6.14. This is in the better half of the industry: SLDB outperforms 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 6.14
Quick Ratio 6.14
SLDB Yearly Current Assets VS Current LiabilitesSLDB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. SLDB Growth Analysis

3.1 Past

  • SLDB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.55%, which is quite impressive.
EPS 1Y (TTM)33.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SLDB will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.27% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2.82%
EPS Next 2Y0.72%
EPS Next 3Y12.17%
EPS Next 5Y19.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLDB Yearly Revenue VS EstimatesSLDB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
SLDB Yearly EPS VS EstimatesSLDB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. SLDB Valuation Analysis

4.1 Price/Earnings Ratio

  • SLDB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SLDB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLDB Price Earnings VS Forward Price EarningsSLDB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLDB Per share dataSLDB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SLDB's earnings are expected to grow with 12.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.72%
EPS Next 3Y12.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SLDB Dividend Analysis

5.1 Amount

  • SLDB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SLDB Fundamentals: All Metrics, Ratios and Statistics

SOLID BIOSCIENCES INC

NASDAQ:SLDB (3/27/2026, 8:00:03 PM)

After market: 7.25 +0.14 (+1.97%)

7.11

-0.62 (-8.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19
Earnings (Next)05-13
Inst Owners85.87%
Inst Owner Change0.01%
Ins Owners1.22%
Ins Owner Change2.45%
Market Cap553.94M
Revenue(TTM)N/A
Net Income(TTM)-174.32M
Analysts86.32
Price Target17.34 (143.88%)
Short Float %14.65%
Short Ratio6.93
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3.71%
Min EPS beat(2)-7.27%
Max EPS beat(2)-0.15%
EPS beat(4)1
Avg EPS beat(4)1.71%
Min EPS beat(4)-7.27%
Max EPS beat(4)18.31%
EPS beat(8)3
Avg EPS beat(8)-2.37%
EPS beat(12)7
Avg EPS beat(12)3.64%
EPS beat(16)8
Avg EPS beat(16)-2.69%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.09%
PT rev (3m)11.62%
EPS NQ rev (1m)11.43%
EPS NQ rev (3m)11.73%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.08
P/tB 3.08
EV/EBITDA N/A
EPS(TTM)-2.02
EYN/A
EPS(NY)-2.08
Fwd EYN/A
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS0
BVpS2.31
TBVpS2.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -74.97%
ROE -96.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.5%
ROA(5y)-48.03%
ROE(3y)-69.2%
ROE(5y)-61.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.14
Quick Ratio 6.14
Altman-Z -1.09
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)70.22%
Cap/Depr(5y)55.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47%
EPS Next Y-2.82%
EPS Next 2Y0.72%
EPS Next 3Y12.17%
EPS Next 5Y19.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-37.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-43.28%
EBIT Next 3Y-25.8%
EBIT Next 5YN/A
FCF growth 1Y-5.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.19%
OCF growth 3YN/A
OCF growth 5YN/A

SOLID BIOSCIENCES INC / SLDB Fundamental Analysis FAQ

What is the fundamental rating for SLDB stock?

ChartMill assigns a fundamental rating of 3 / 10 to SLDB.


What is the valuation status of SOLID BIOSCIENCES INC (SLDB) stock?

ChartMill assigns a valuation rating of 0 / 10 to SOLID BIOSCIENCES INC (SLDB). This can be considered as Overvalued.


Can you provide the profitability details for SOLID BIOSCIENCES INC?

SOLID BIOSCIENCES INC (SLDB) has a profitability rating of 1 / 10.


What is the earnings growth outlook for SOLID BIOSCIENCES INC?

The Earnings per Share (EPS) of SOLID BIOSCIENCES INC (SLDB) is expected to decline by -2.82% in the next year.